دورية أكاديمية
أعرض في EDS

PRC2 loss drives MPNST metastasis and matrix remodeling.

التفاصيل البيبلوغرافية
العنوان: PRC2 loss drives MPNST metastasis and matrix remodeling.
المؤلفون: Brockman QR; Department of Internal Medicine.; Molecular Medicine Training Program., Scherer A; Department of Internal Medicine., McGivney GR; Department of Internal Medicine.; Cancer Biology Training Program.; Department of Molecular Physiology and Biophysics., Gutierrez WR; Department of Internal Medicine.; Cancer Biology Training Program.; Medical Scientist Training Program., Voigt AP; Molecular Medicine Training Program.; Medical Scientist Training Program.; Department of Ophthalmology and Visual Science., Isaacson AL; Department of Pathology., Laverty EA; Department of Internal Medicine., Roughton G; Department of Internal Medicine., Knepper-Adrian V; Department of Internal Medicine., Darbro B; Department of Pediatrics, and., Tanas MR; Department of Pathology., Stipp CS; Department of Molecular Physiology and Biophysics.; Department of Biology, University of Iowa, Iowa City, Iowa, USA., Dodd RD; Department of Internal Medicine.
المصدر: JCI insight [JCI Insight] 2022 Oct 24; Vol. 7 (20). Date of Electronic Publication: 2022 Oct 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Neurofibrosarcoma*/genetics , Neurofibrosarcoma*/pathology, Mice ; Animals ; Mutation ; Histone Methyltransferases ; Fibrosis
مستخلص: The histone methyltransferase PRC2 plays a complex role in cancer. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with frequent loss-of-function mutations in PRC2 that are associated with poor outcome. Here, we identify a critical role for PRC2 loss in driving MPNST metastasis. PRC2-dependent metastatic phenotypes included increased collagen-dependent invasion, upregulation of matrix-remodeling enzymes, and elevated lung metastasis in orthotopic mouse models. Furthermore, clinical sample analysis determined that PRC2 loss correlated with metastatic disease, increased fibrosis, and decreased survival in patients with MPNSTs. These results may have broad implications for PRC2 function across multiple cancers and provide a strong rationale for investigating potential therapies targeting ECM-remodeling enzymes and tumor fibrosis to improve outcomes in patients with MPNSTs.
References: Int J Clin Exp Pathol. 2014 Aug 15;7(9):6040-7. (PMID: 25337249)
Antioxidants (Basel). 2021 Feb 19;10(2):. (PMID: 33669630)
Cancer Res. 2018 Feb 15;78(4):845-852. (PMID: 29437766)
Am J Clin Pathol. 2017 Aug 01;148(2):179-189. (PMID: 28898989)
Nat Commun. 2018 Jun 29;9(1):2547. (PMID: 29959321)
Nat Genet. 2014 Nov;46(11):1227-32. (PMID: 25240281)
Nat Struct Mol Biol. 2018 Mar;25(3):225-232. (PMID: 29483650)
Ann Oncol. 2011 Jan;22(1):207-214. (PMID: 20656792)
Cancer Med. 2019 Sep;8(11):5232-5241. (PMID: 31278855)
Nat Commun. 2017 Jul 10;8:15999. (PMID: 28691711)
Nat Protoc. 2013 Nov;8(11):2281-2308. (PMID: 24157548)
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3735-44. (PMID: 27303043)
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. (PMID: 30867289)
Cell. 2014 Aug 28;158(5):1110-1122. (PMID: 25171411)
Am J Transl Res. 2019 Sep 15;11(9):5301-5312. (PMID: 31632511)
Nat Rev Drug Discov. 2014 Dec;13(12):904-27. (PMID: 25376097)
Oncogene. 2005 Feb 10;24(7):1244-51. (PMID: 15558013)
Clin Cancer Res. 2009 Jan 1;15(1):247-55. (PMID: 19118052)
Br J Cancer. 2006 Apr 10;94(7):941-6. (PMID: 16538215)
Cancer Cell. 2016 Jan 11;29(1):17-31. (PMID: 26766588)
Nat Commun. 2014;5:3127. (PMID: 24457600)
Nanomedicine. 2013 Feb;9(2):151-8. (PMID: 22841910)
Cancer Res. 2019 Jul 1;79(13):3205-3219. (PMID: 30898839)
Sci Rep. 2016 Jan 25;6:19608. (PMID: 26804196)
Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57. (PMID: 19546857)
Nat Cell Biol. 2012 Aug;14(8):777-83. (PMID: 22854810)
Int J Cancer. 2019 Sep 1;145(5):1254-1269. (PMID: 31008529)
Methods Enzymol. 2012;504:183-200. (PMID: 22264535)
Clin Cancer Res. 2020 Sep 15;26(18):5036-5047. (PMID: 32718998)
Nature. 2014 Oct 9;514(7521):247-51. (PMID: 25119042)
Nature. 2002 Oct 10;419(6907):624-9. (PMID: 12374981)
Cell. 2019 Jan 10;176(1-2):98-112.e14. (PMID: 30633912)
Mod Pathol. 2016 Jun;29(6):582-90. (PMID: 26990975)
Nat Rev Mol Cell Biol. 2015 Nov;16(11):643-649. (PMID: 26420232)
J Cancer. 2019 Feb 23;10(6):1375-1384. (PMID: 31031847)
Sci Rep. 2017 Jun 15;7(1):3568. (PMID: 28620234)
J Cancer. 2019 Oct 20;10(26):6481-6490. (PMID: 31777578)
Nat Rev Cancer. 2016 Dec;16(12):803-810. (PMID: 27658528)
Neurooncol Adv. 2019 Sep 10;2(Suppl 1):i75-i84. (PMID: 32642734)
Nucleic Acids Res. 2019 May 7;47(8):e47. (PMID: 30783653)
Nat Commun. 2018 Jul 18;9(1):2801. (PMID: 30022044)
Am J Cancer Res. 2018 Mar 01;8(3):422-434. (PMID: 29636998)
PLoS One. 2015 Jun 01;10(6):e0126466. (PMID: 26030458)
Oncotarget. 2017 Jul 04;8(62):104785-104795. (PMID: 29285213)
Mol Cancer Ther. 2016 Oct;15(10):2370-2377. (PMID: 27466357)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Oncogene. 2017 Nov 23;36(47):6542-6554. (PMID: 28759046)
Cells. 2019 Aug 27;8(9):. (PMID: 31461880)
Genes (Basel). 2020 May 23;11(5):. (PMID: 32456131)
Development. 2014 Dec;141(23):4610-7. (PMID: 25359725)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Cancer Res. 2017 Aug 15;77(16):4486-4497. (PMID: 28646022)
Mol Cancer Ther. 2013 Sep;12(9):1906-17. (PMID: 23858101)
Cancer Res. 2007 Nov 15;67(22):10657-63. (PMID: 18006806)
PLoS One. 2012;7(1):e30393. (PMID: 22272343)
J Clin Invest. 2015 May;125(5):1927-43. (PMID: 25844900)
Nat Commun. 2022 May 10;13(1):2543. (PMID: 35538070)
Lancet Oncol. 2014 Apr;15(4):415-23. (PMID: 24618336)
معلومات مُعتمدة: P30 CA086862 United States CA NCI NIH HHS; R01 NS119322 United States NS NINDS NIH HHS; T32 GM139776 United States GM NIGMS NIH HHS
فهرسة مساهمة: Keywords: Cancer; Epigenetics; Mouse models; Oncology
المشرفين على المادة: EC 2.1.1.- (Histone Methyltransferases)
تواريخ الأحداث: Date Created: 20220906 Date Completed: 20221025 Latest Revision: 20230618
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9714789
DOI: 10.1172/jci.insight.157502
PMID: 36066973
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.157502